Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29359902 | 1.00 | BTK (1.00) | BTK | |
| SCHEMBL1067909 | 0.97 | BTK (0.94) | BTK | |
| SCHEMBL1067840 | 0.95 | BTK (1.00) | BTK | |
| SCHEMBL770592 | 0.94 | BTK (0.89) | BTK | |
| SCHEMBL1069710 | 0.93 | BTK (0.88) | BTK | |
| SCHEMBL1069586 | 0.93 | BTK (0.87) | BTK | |
| SCHEMBL1068279 | 0.93 | BTK (0.87) | BTK | |
| SCHEMBL1069889 | 0.93 | BTK (0.86) | BTK | |
| SCHEMBL1070993 | 0.93 | BTK (0.86) | BTK | |
| SCHEMBL1069168 | 0.93 | BTK (0.89) | BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 960 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260124242-A1 | EXPANSION OF TUMOR INFILTRATING LYMPHOCYTES FROM LIQUID TUMORS AND THERAPEUTIC USES THEREOF | IOVANCE BIOTHERAPEUTICS INC (US) | 2026-05-07 | — | — | US | claimed |
| US-20250361307-A1 | COMBINATION THERAPIES FOR TREATING HYPERPROLIFERATIVE DISORDERS | X4 PHARMACEUTICALS INC (US) | 2025-11-27 | — | — | US | claimed |
| WO-2024239512-A1 | PHARMACEUTICAL COMBINATION AND USE THEREOF IN TREATMENT OF CANCER | 劲方医药科技(上海)有限公司 | 2024-11-28 | — | — | WO | claimed |
| WO-2024240025-A1 | COMBINED PHARMACEUTICAL COMPOSITION AND USE THEREOF | 无锡瓴方生物医药科技有限公司 | 2024-11-28 | — | — | WO | claimed |
| CN-118987211-A | Combined medicine composition and application thereof | 无锡瓴方生物医药科技有限公司 | 2024-11-22 | — | — | CN | claimed |
| CN-118161618-A | Combination product comprising a Bcl-2 inhibitor or a Bcl-2/Bcl-xL inhibitor and use thereof | 苏州亚盛药业有限公司 | 2024-06-11 | — | — | CN | claimed |
| WO-2024098024-A1 | EXPANSION OF TUMOR INFILTRATING LYMPHOCYTES FROM LIQUID TUMORS AND THERAPEUTIC USES THEREOF | IOVANCE BIOTHERAPEUTICS, INC. (US) | 2024-05-10 | — | — | WO | claimed |
| CN-113786409-B | Compositions comprising phosphoinositide 3-kinase inhibitors and a second antiproliferative agent | 甫康（上海）健康科技有限责任公司 | 2024-04-02 | — | — | CN | claimed |
| CN-114788830-B | Application of small molecule inhibitor capable of inhibiting toxoplasma proliferation | 东阳市人民医院 | 2024-01-23 | — | — | CN | claimed |
| WO-2023240258-A1 | COMBINATION THERAPIES FOR TREATING HYPERPROLIFERATIVE DISORDERS | X4 PHARMACEUTICALS, INC. (US) | 2023-12-14 | — | — | WO | claimed |
| CN-107872977-B | Combination of an IRAK4 inhibitor and a BTK inhibitor | 拜耳制药股份公司 | 2021-07-09 | — | — | CN | claimed |
| EP-3471735-A2 | PHARMACEUTICAL COMPOSITIONS AND THEIR USE FOR TREATMENT OF CANCER AND AUTOIMMUNE DISEASES | Zhejiang Dtrm Biopharma Co. Ltd. (CN) | 2019-04-24 | — | — | EP | claimed |
| US-20180289685-A1 | COMBINATIONS OF INHIBITORS OF IRAK4 WITH INHIBITORS OF BTK | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-10-11 | — | — | US | claimed |
| EP-3288558-A1 | COMBINATIONS OF INHIBITORS OF IRAK4 WITH INHIBITORS OF BTK | Bayer Pharma Aktiengesellschaft (DE) | 2018-03-07 | — | — | EP | claimed |
| WO-2017218844-A2 | PHARMACEUTICAL COMPOSITIONS AND THEIR USE FOR TREATMENT OF CANCER AND AUTOIMMUNE DISEASES | Zhejiang DTRM Biopharma Co. Ltd. (CN) | 2017-12-21 | — | — | WO | claimed |
| EP-3195865-A1 | COMBINATIONS OF INHIBITORS OF IRAK4 WITH INHIBITORS OF BTK | Bayer Pharma Aktiengesellschaft (DE) | 2017-07-26 | — | — | EP | claimed |
| WO-2016174183-A1 | COMBINATIONS OF INHIBITORS OF IRAK4 WITH INHIBITORS OF BTK | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-11-03 | — | — | WO | claimed |
| EP-1863766-B1 | CERTAIN SUBSTITUTED AMIDES, METHOD OF MAKING, AND METHOD OF USE THEREOF | GILEAD CONNECTICUT INC (US) | 2015-05-20 | — | — | EP | claimed |
| US-7947835-B2 | Certain substituted amides, method of making, and method of use thereof | CGI PHARMACEUTICALS, INC. (US) | 2011-05-24 | — | — | US | claimed |
| US-20060229337-A1 | Certain substituted amides, method of making, and method of use thereof | GILEAD CONNECTICUT, INC. | 2006-10-12 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260124242-A1 | EXPANSION OF TUMOR INFILTRATING LYMPHOCYTES FROM LIQUID TUMORS AND THERAPEUTIC USES THEREOF | PBK, LTK, BLK | BTK 5/4885 |
| US-20060229337-A1 | Certain substituted amides, method of making, and method of use thereof | BTK, SYK, MYD88 | BTK 1/4885 |
| US-20180289685-A1 | COMBINATIONS OF INHIBITORS OF IRAK4 WITH INHIBITORS OF BTK | IRAK4, IRAK1, IRAK2 | BTK 5/4885 |
| US-20250361307-A1 | COMBINATION THERAPIES FOR TREATING HYPERPROLIFERATIVE DISORDERS | CXCR6, BCL6, CXCR4 | BTK 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.